A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.

Trial Profile

A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Everolimus (Primary) ; Trastuzumab; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BOLERO-3
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 18 Apr 2016 Results of a pooled biomarker analysis form BOLERO-1 and BOLERO-3 trials (n=549) published in the Journal of Clinical Oncology
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium (n = 569).
    • 13 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top